Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects

Journal of Clinical Pharmacology

Volumn 50, Issue 10, 2010, Pages 1151-1158

  You, Joyce H S ^a   Chan, Winnie K Y ^a   Chung, Polly F P ^a   Miao Hu, ^a   Tomlinson, Brian ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Diltiazem; drug interaction; low density lipoprotein cholesterol; pharmacodynamics; simvastatin

Indexed keywords

DILTIAZEM; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; EVENING DOSAGE; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DILTIAZEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN;

EID: 77958529099     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009358082     Document Type: Article

References (39)

1. Neuvonen PJ, Niemi M., Backman JT Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 ; 80: 565-581.
2. Mousa O., Brater DC, Sunblad KJ, Hall SD The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000 ; 67: 267-274.
3. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998 ; 64: 369-377.
4. Yeo KR, Yeo WW, Wallis EJ, Ramsay LE Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharmacol. 1999 ; 48: 610-615.
5. Jones TE, Morris RG, Mathew TH Diltiazem-cyclosporin pharmacokinetic interaction-dose-response relationship. Br J Clin Pharmacol. 1997 ; 44: 499-504.
6. Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DW Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy. 1994 ; 14: 471-481.
7. McLachlan AJ, Tett SE Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Therapeutic Drug Monitoring. 1998 ; 20: 390-395.
8. Kumana CR, Tong MK, Li CS, et al. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. Br J Clin Pharmacol. 2003 ; 56: 670-678.
9. Neuvonen P., Kantola T., Kivisto K. Calcium channel blocker-simvastatin interaction [letter]. Clin Pharmacol Ther. 1999 ; 65: 583-585.
10. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999 ; 84: 811-815.
11. Tobert JA, Vega JM, Dobrinska M., Gruer PJ Calcium channel blocker-simvastatin interaction [letter]. Clin Pharmacol Ther. 1999 ; 65: 583.
12. Yeung PK, Montague TJ, Tsui B., McGregor C. High-performance liquid chromatographic assay of diltiazem and six of its metabolites in plasma: application to a pharmacokinetic study in healthy volunteers. J Pharm Sci. 1989 ; 78: 592-597.
13. Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol. 1998 ; 82: 311-316.
14. Watanabe H., Kosuge K., Nishio S., et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 2004 ; 76: 281-292.
15. Yeo KR, Yeo WW Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol. 2001 ; 51: 461-470.
16. Varis T., Backman JT, Kivisto KT, Neuvonen PJ Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther. 2000 ; 67: 215-221.
17. Laganiere S., Davies RF, Carignan G., et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther. 1996 ; 60: 255-264.
18. Varhe A., Olkkola KT, Neuvonen PJ Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther. 1996 ; 59: 369-375.
19. Fujino H., Saito T., Tsunenari Y., Kojima J., Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004 ; 34: 961-971.
20. Caraco Y., Wilkinson GR, Wood AJ Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther. 1996 ; 60: 396-404.
21. Lin Y., Anderson GD, Kantor E., Ojemann LM, Wilensky AJ Differences in the urinary excretion of 6-beta-hydroxycortisol/ cortisol between Asian and Caucasian women. J Clin Pharmacol. 1999 ; 39: 578-582.
22. Xie HG, Kim RB, Wood AJ, Stein CM Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001 ; 41: 815-850.
23. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998 ; 81: 582-587. (Pubitemid 28182422)
24. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92: 152-160.
25. Kim KA, Park PW, Lee OJ, Kang DK, Park JY Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2007 ; 47: 87-93.
26. Chen C., Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 ; 33: 537-546.
27. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2008 ; 84: 457-461.
28. Pasanen MK, Neuvonen M., Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006 ; 16: 873-879.
29. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S., Hall SD Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther. 1999 ; 290: 1116-1125.
30. Mayhew BS, Jones DR, Hall SD An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos. 2000 ; 28: 1031-1037.
31. Sutton D., Butler AM, Nadin L., Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 ; 282: 294-300.
32. Zhang X., Quinney SK, Gorski JC, Jones DR, Hall SD Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos. 2009 ; 37: 1587-1597.
33. Peces R., Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron. 2001 ; 89: 117-118.
34. Kanathur N., Mathai MG, Byrd RP, Jr., Fields CL, Roy TM Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001 ; 94: 339-341.
35. Lewin JJ 3rd, Nappi JM, Taylor MH Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002 ; 36: 1546-1549.
36. Potentially fatal interaction between diltiazem and statins. Ann Intern Med. 2004 ; 140: W31.
37. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008 ; 168: 721-727.
38. Glasziou PP, Irwig L., Heritier S., Simes RJ, Tonkin A. Monitoring cholesterol levels: measurement error or true change ? Ann Intern Med. 2008 ; 148: 656-661.
39. Pereira MA, Weggemans RM, Jacobs DR, Jr., et al. Within-person variation in serum lipids: implications for clinical trials. Int J Epidemiol. 2004 ; 33: 534-541.